Piper Sandler maintains neutral on Apellis stock, $32 target
Piper Sandler reaffirmed its Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a steady price target of $32.00. The firm's analysis was based on a recent survey of ophthalmologists ...
The secret behind sharp vision: New research reveals the benefits of tiny eye movements
Even when we think we are holding our gaze perfectly still, our eyes make tiny, involuntary movements. While these ...